Regulatory approval
Published by the Health Canada.
Health Canada approved asciminib for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received 1 or more tyrosine kinase inhibitors.
This is written in the approval document as:
SCEMBLIX (asciminib tablets) is indicated for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received one or more tyrosine kinase inhibitors.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HC (1) | BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| HC (1) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib |